# GentiBio

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/gentibio

- Industry: Biotechnology
- Headquarters: Cambridge, US
- Website: www.gentibio.com
- Total disclosed funding: $177M
- Latest round: Series A (Aug 11, 2021)
- Investors on record: 7

## About

Based in Massachusetts, US, and founded in 2020 by co-founders Adel Nada, Andy Walker,  and Chandra Patel. GentiBio, Inc. operates as a biotherapeutics company that develops engineered regulatory T cells to treat autoimmune allergic diseases. In August 2021, GentiBio, Inc. received USD 157 million in Series A funding from Matrix Capital Management, Avidity Partners, JDRF T1D Fund, OrbiMed, RA Capital Management, Novartis Venture Fund, and Seattle Children's Research Institute.

The company offers Tregs that operates a central role in keeping the immune system in check by combining insights from Tregs biology and antigen receptor engineering that enable the treatment of autoimmune, alloimmune, auto-inflammatory, and allergic diseases.

GentiBio, Inc. plans to use the August 2021 funding to advance its potential functional cure for Type 1 Diabetes (T1D) to the clinic alongside multiple other pipeline programs in chronic autoimmunity and auto-inflammation. In the year 2021, GentiBio is currently selecting its clinical candidate for T1D and will begin IND-enabling studies before the end of 2021.

## Funding rounds

- Series A, Aug 11, 2021, $157M — OrbiMed Advisors, Novartis Venture Fund, Seattle Children's Hospital Endowment, RA Capital Management, Matrix Capital Management, JDRF T1D Fund, Avidity Partners Management
- Seed, Aug 5, 2020, $20M — OrbiMed Advisors, Novartis Venture Fund, RA Capital Management

## Investors

- OrbiMed Advisors (https://capitalatlas.ai/funds/orbimed-advisors) — Seed, Series A
- Novartis Venture Fund (https://capitalatlas.ai/funds/novartis-venture-fund) — Seed, Series A
- RA Capital Management (https://capitalatlas.ai/funds/ra-capital-management) — Seed, Series A
- Seattle Children's Hospital Endowment — Series A
- Matrix Capital Management — Series A
- JDRF T1D Fund (https://capitalatlas.ai/funds/jdrf-t1d-fund) — Series A
- Avidity Partners Management — Series A